In March 2024, a pivotal clinical trial was launched to evaluate what might well become the first new tuberculosis vaccine on the market in more than a century. As anticipation mounts for the trial to ...
VPM1002 is a live recombinant vaccine created by genetically modifying BCG. It was originally developed in Germany and licensed to the Serum Institute of India. The trial compared VPM1002 with BCG in ...
South Africa could be on the verge of its first new TB vaccine in more than a century, but a successful jab will only change ...